Komzifti in Nepal
How patients in Nepal access Komzifti (ziftomenib) via Named Patient Program.
Komzifti - overview
Komzifti (ziftomenib) is an oral menin inhibitor manufactured by Kura Oncology. The US FDA approved Komzifti in 2025 for adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying NPM1 mutations, which represent roughly 30 percent of de-novo adult AML. Mechanistically, ziftomenib blocks the menin-KMT2A protein interaction that drives aberrant HOXA9 and MEIS1 transcription in NPM1-mutant and KMT2A-rearranged leukemias. Standard dosing is 600 mg orally once daily on a 28-day cycle, taken with food, continued until disease progression or unacceptable toxicity. The pivotal KOMET-001 single-arm trial reported a complete remission rate near 25 percent in heavily pre-treated R/R NPM1-mutant AML with a median duration of response above six months. Key safety signals include differentiation syndrome, QTc prolongation, and cytopenias, all of which require structured monitoring in the first eight weeks.
For a patient in Nepal with a confirmed NPM1-mutant R/R AML diagnosis, Komzifti is not registered with the Department of Drug Administration (DDA) and is not available through hospital formularies. Supply is therefore organized through Nepal's personal-use import framework, which Reserve Meds coordinates end-to-end with the treating haematologist.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Access pathway in Nepal
Nepal's Department of Drug Administration (DDA) sits under the Ministry of Health and Population and regulates the import, registration, and dispensing of all medicinal products under the Drugs Act 1978 and subsequent rules. For an unregistered specialty oncologic agent like Komzifti, the legal route is the personal-use import pathway: an individual patient, supported by a licensed treating physician in Nepal, may import a defined quantity of medicine for personal therapeutic use upon DDA authorisation. The volume of NPP imports in Nepal is small but the procedural framework is established and routinely used for rare oncologic, haematologic, and genetic-disease therapies sourced from the United States, the United Kingdom, India, and Europe.
Operationally the workflow runs through the patient's treating haematologist or medical oncologist at one of the principal tertiary centres: Bhaktapur Cancer Hospital, B.P. Koirala Memorial Cancer Hospital in Bharatpur, Civil Service Hospital Kathmandu, or one of the private centres such as Norvic International Hospital or Grande International Hospital. The treating physician issues a prescription accompanied by a detailed clinical justification letter referencing the NPM1 mutation report, prior lines of therapy, and the absence of an in-country alternative.
Regulatory and Named-Patient Access details
The DDA personal-use authorisation is granted on a per-patient, per-shipment basis. The treating physician's letter must cite the FDA approval status, the clinical indication, and the rationale for not using locally available alternatives (typically because none exist for NPM1-mutant R/R AML). The DDA reviews the application and issues an import authorisation letter that the importer of record presents to Nepal Customs at the point of entry, typically Tribhuvan International Airport. Reserve Meds operates as a coordination intermediary: we do not act as importer of record inside Nepal, but we structure the cross-border shipment from a US DSCSA-compliant specialty wholesaler, prepare the regulatory packet, and hand the documentation to the patient's nominated agent or hospital pharmacy.
Komzifti is heat-stable and does not require cold-chain handling, which simplifies logistics relative to biologics. Each shipment carries a US-pedigree certificate, manufacturer lot and expiry data, and a chain-of-custody record.
Documentation required
The patient and physician should be prepared to provide: a current Nepali citizenship document or passport; a recent bone-marrow biopsy report confirming AML with NPM1 mutation status; the molecular pathology report identifying the specific NPM1 variant; documentation of prior induction and salvage therapy; a current prescription from the treating Nepali physician; the physician's clinical justification letter on hospital letterhead; the DDA personal-use import application form; and evidence of payment capacity for the prepaid course. Reserve Meds prepares the cross-border commercial documentation, the manufacturer pedigree, and the customs packet.
Typical timeline for Nepal
From first contact to delivered drug, most cases complete within four to six weeks. Week 0 to 1 covers clinical eligibility review and document gathering. Week 1 to 2 covers DDA filing and prescription preparation. Week 2 to 4 covers procurement from the US wholesaler, export documentation, and air freight to Kathmandu. Week 4 to 6 covers customs clearance and final dispensing to the treating physician or hospital pharmacy. Re-supply cycles for chronic dosing are typically faster (two to three weeks) once the initial pathway is established and the DDA authorisation is renewed.
Costs and funding considerations
Komzifti has a US wholesale acquisition cost in the range of USD 35,000 to 45,000 per 28-day cycle. A six-month course therefore falls in the USD 210,000 to 270,000 band before shipping, regulatory fees, and Reserve Meds coordination. In Nepalese rupees this is roughly NPR 28 to 36 million for a six-month course. Nepal does not have a public oncology reimbursement programme that covers unregistered foreign therapies. The Bipanna Nagarik Aushadhi Upchar Kosh (Citizens Critical Illness Treatment Fund) does provide limited support for cancer treatment but reimbursement for personal-import unregistered agents is rare. Private insurance coverage is also rare for this scenario. Most families fund the course through a combination of personal resources, diaspora family support, and structured prepayment arrangements with Reserve Meds.
Frequently asked questions
- Is the pathway legal in Nepal? Yes. It operates under the DDA personal-use import authorisation framework set out in the Drugs Act 1978 and the Drug Standard Regulations.
- Does my insurance cover Komzifti? Typically no. Unregistered personal-import oncology therapy is generally outside private and public coverage in Nepal. Patient prepayment is the norm.
- What physician credentials are required? A Nepal Medical Council registered physician, typically a haematologist or medical oncologist at a recognised tertiary centre, who issues the prescription and clinical justification.
- What if Komzifti is in short supply at the US level? Reserve Meds will inform you upfront and decline the case rather than commit to a timeline we cannot meet. We do not source from grey-market channels.
- Can I arrange ongoing re-supply? Yes. Once the initial DDA authorisation and clinical baseline are established, monthly re-supply is straightforward.
- Do I need to travel to the US? No. The drug is dispensed to your treating physician in Nepal; clinical management remains in-country.
Start a request for Komzifti in Nepal
If your haematologist has confirmed NPM1-mutant R/R AML and you want to walk through the Nepal pathway in detail, open a case file with Reserve Meds. We will review the eligibility documentation, prepare the DDA packet alongside your treating physician, and produce a delivered quote within 24 hours.